赛诺菲和再生元制药公司宣布,其Dupixent药物用于治疗慢性特发性荨麻疹的授权申请在欧盟取得重要进展,获得了人用药品委员会(CHMP)的积极意见。这一积极意见为该药物在欧盟市场的最终批准铺平了道路。
赛诺菲和再生元制药公司宣布,其Dupixent药物用于治疗慢性特发性荨麻疹的授权申请在欧盟取得重要进展,获得了人用药品委员会(CHMP)的积极意见。这一积极意见为该药物在欧盟市场的最终批准铺平了道路。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.